Relative anti-HIV-1 efficacy of lamivudine and emtricitabine in vitro is dependent on cell type

Journal of Acquired Immune Deficiency Syndromes

Volumn 32, Issue 3, 2003, Pages 255-258

  Hazen, Richard ^a   Lanier, E Randall ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Emtricitabine; HIV 1; Lamivudine; MT 4 cells

Indexed keywords

ANTIRETROVIRUS AGENT; EMTRICITABINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL TYPE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOID CELL LINE; MACROPHAGE; MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS STRAIN;

ANTI-HIV AGENTS; CELLS, CULTURED; DEOXYCYTIDINE; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; LAMIVUDINE; LEUKOCYTES, MONONUCLEAR; MACROPHAGES; T-LYMPHOCYTES;

EID: 0037340618     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200303010-00003     Document Type: Article

References (21)

1. Soudeyns H, Yao X-J, Gao Q, et al. Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2′-deoxy-3′-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob Agents Chemother 1991; 35: 1386-90.
2. Schinazi R, McMillan A, Cannon D, et al. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine. Antimicrob Agents Chemother 1992;36:2423-31.
3. Shewach D, Liotta D, Schinazi R. Affinity of the antiviral enantiomers of oxathiolane cytosine nucleotides for human 2′-deoxycytidine kinase. Biochem Pharmacol 1993;45:1540-3.
4. Tisdale M, Kemp S, Parry N, et al. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993;90:5653-6.
5. Schinazi R, Lloyd R, Nguyen M, et al. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother 1993;37:875-81.
6. Koyanagi Y, Harada S, Takahashi M, et al. Selective cytotoxicity of AIDS virus infection towards HTLV-I-transformed cell lines. Int J Cancer 1985;36:445-51.
7. Boucher C, Cammack N, Schipper P, et al. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1993;37:2231-4.
8. Popovic M, Sarngadharan M, Read E, et al. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984;224:497-500.
9. Gartner S, Markovits P, Markovitz D, et al. The role of mononuclear phagocytes in HTLV-III/LAV infection, Science 1986; 233: 215-9.
10. St. Clair M, Martin JL, Tudor-Williams G, et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-I reverse transcriptase. Science 1991;253:1557-9.
11. Schwartz O, Henin Y, Marechal V, et al. A rapid and simple colorimetric test for the study of anti-HIV agents. AIDS Res Hum Retroviruses 1988;4:441-8.
12. Averett D. Anti-HIV compound assessment by two novel high- capacity assays. J Virol Methods 1989:23:263-76.
13. Hill A. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. J Physiol (London) 1910; 40:4-8.
14. Mager M. Data analysis in biochemistry and biophysics. New York: Academic Press, 1972.
15. Richman DD. Antiretroviral activity of emtricitabine, a potent nucleoside reverse transcriptase inhibitor. Antiviral Ther 2001:6: 83-8.
16. Mathez D, Schinazi DF, Liotta DC, et al. Infectious amplification of wild-type human immunodeficiency virus from patients' lymphocytes and modulation by reverse transcriptase inhibitors in vitro. Antimicrob Agents Chemother 1993;37:2206-11.
17. Delehanty J, Wakeford C, Hulett L, et al. A phase I/II randomized, controlled study of FTC versus 3TC in HIV-infected patients [abstract 16]. Presented at the 6th Retroviruses Opport Infect, 1999.
18. Harris J, Shaw A, Borroto-Esoda K, et al. Genotype analysis of HIV-1 infected ART naive patients receiving emtricitabine (FTC) or lamivudine (3TC) in a double blind equivalence trial. Antiviral Ther 2001;6(Suppl 1):78-9.
19. Daluge S, Good S, Faletto M, et al. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob Agents Chemother 1997;41: 1082-93.
20. Kuritzkes D, Quinn J, Benoit S, et al. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients, AIDS 1996;10:975-81.
21. Staszewski S, Katlama C, Harrer T, et al. A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects. AIDS 1998:12(Suppl):F197-202.